Craig Lee

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study
    Craig R Lee
    Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Pharmacogenet Genomics 17:349-58. 2007
  2. ncbi Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers
    Craig R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA
    Am J Cardiol 109:651-7. 2012
  3. ncbi Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism
    Katherine N Theken
    Div of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, Univ of North Carolina, Chapel Hill, NC 27599, USA
    Am J Physiol Endocrinol Metab 302:E500-9. 2012
  4. ncbi Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans
    Craig R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599 7569, USA
    Hypertension 57:116-22. 2011
  5. ncbi CYP2C9 genotype as a predictor of drug disposition in humans
    C R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Methods Find Exp Clin Pharmacol 26:463-72. 2004
  6. ncbi Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals
    Craig R Lee
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599 7360, USA
    Pharmacotherapy 23:720-5. 2003
  7. ncbi Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes
    Craig R Lee
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, NC 27599 7360, Chapel Hill, USA
    Eur J Clin Pharmacol 58:791-4. 2003
  8. ncbi Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27517, USA
    J Am Coll Cardiol 46:497-504. 2005
  9. ncbi Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
    Craig R Lee
    Divisions of Pharmacotherapy, CB# 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA
    J Clin Pharmacol 43:84-91. 2003
  10. ncbi Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes
    Craig R Lee
    Divisions of Pharmacotherapy and Cardiology, University of North Carolina at Chapel Hill, USA
    Clin Pharmacol Ther 72:562-71. 2002

Research Grants

  1. CYP2J2 Derived Eicosanoids and Endothelial Function
    Craig Lee; Fiscal Year: 2005
  2. Cytochrome P450 Derived Eicosanoids and Inflammation
    Craig R Lee; Fiscal Year: 2010

Collaborators

Detail Information

Publications26

  1. ncbi CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study
    Craig R Lee
    Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Pharmacogenet Genomics 17:349-58. 2007
    ..The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if genetic variation in CYP2J2 and CYP2C8 was associated with coronary heart disease risk...
  2. ncbi Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers
    Craig R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA
    Am J Cardiol 109:651-7. 2012
    ....
  3. ncbi Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism
    Katherine N Theken
    Div of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, Univ of North Carolina, Chapel Hill, NC 27599, USA
    Am J Physiol Endocrinol Metab 302:E500-9. 2012
    ..Future studies delineating the underlying mechanisms and evaluating the therapeutic potential of modulating CYP-derived EETs and 20-HETE in metabolic diseases are warranted...
  4. ncbi Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans
    Craig R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599 7569, USA
    Hypertension 57:116-22. 2011
    ....
  5. ncbi CYP2C9 genotype as a predictor of drug disposition in humans
    C R Lee
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Methods Find Exp Clin Pharmacol 26:463-72. 2004
    ..Collectively, these findings suggest that CYP2C9 genotype-guided dosing may be clinically useful and warrants prospective investigation...
  6. ncbi Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals
    Craig R Lee
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599 7360, USA
    Pharmacotherapy 23:720-5. 2003
    ..To determine if differences in the pharmacokinetics of losartan and its pharmacologically active E3174 metabolite exist among individuals expressing the cytochrome P450 (CYP) 2C9*1/*1, *1/*2, and *1/*3 genotypes...
  7. ncbi Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes
    Craig R Lee
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, NC 27599 7360, Chapel Hill, USA
    Eur J Clin Pharmacol 58:791-4. 2003
    ..This study was conducted to examine differences in flurbiprofen metabolism among individuals with the CYP2C9*1/*1, *1/*2, and *1/*3 genotypes...
  8. ncbi Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27517, USA
    J Am Coll Cardiol 46:497-504. 2005
    ..The purpose of this study was to investigate the relationship of serum digoxin concentration (SDC) and outcomes in women with heart failure (HF)...
  9. ncbi Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans
    Craig R Lee
    Divisions of Pharmacotherapy, CB# 7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA
    J Clin Pharmacol 43:84-91. 2003
    ..Tolbutamide is a better CYP2C9 probe than flurbiprofen and losartan, and the 0- to 12-hour amount of 4'-hydroxytolbutamide and carboxytolbutamide is the best urinary measure of its metabolism...
  10. ncbi Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes
    Craig R Lee
    Divisions of Pharmacotherapy and Cardiology, University of North Carolina at Chapel Hill, USA
    Clin Pharmacol Ther 72:562-71. 2002
    ..Multiple single-nucleotide polymorphisms in the gene encoding cytochrome P450 (CYP) 2C9 have been identified, but the functional significance of the various putative defective genotypes in humans merits further study...
  11. ncbi Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
    Craig R Lee
    Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599-7360, USA
    Pharmacogenetics 12:251-63. 2002
    ..However, further clinical investigations evaluating the metabolic consequences in individuals expressing the CYP2C9*2, *3, *4, *5, or *6 alleles are required before large-scale clinical genotyping can be recommended...
  12. ncbi NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study
    Craig R Lee
    Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27709, USA
    Pharmacogenet Genomics 16:891-9. 2006
    ..We sought to determine whether cigarette smoking modified the association between NOS3 polymorphisms and risk of coronary heart disease or stroke...
  13. ncbi Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism
    Katherine N Theken
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
    Drug Metab Dispos 39:22-9. 2011
    ..Further study is necessary to determine whether therapeutic restoration of the functional balance between the P450 epoxygenase and ω-hydroxylase pathways is an effective anti-inflammatory strategy...
  14. ncbi Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice
    Yangmei Deng
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599 7569, USA
    FASEB J 25:703-13. 2011
    ....
  15. ncbi Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
    Kyle J Ellis
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7569, Kerr Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 27569, USA
    Pharmacogenomics 10:1799-817. 2009
    ..Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness...
  16. ncbi Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk
    Katherine N Theken
    University of North Carolina at Chapel Hill, Division of Pharmacotherapy and Experimental Therapeutics, CB 7360, Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Pharmacogenomics 8:1369-83. 2007
    ..Future studies in humans validating these relationships and characterizing the underlying mechanisms will be necessary to fully understand the functional role of the CYP epoxygenase pathway in cardiovascular disease...
  17. ncbi Warfarin dosing and the promise of pharmacogenomics
    Todd E Dumas
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Curr Clin Pharmacol 2:11-21. 2007
    ..Therefore, the promise of pharmacogenomic-guided dosing as a useful strategy to improve clinical outcomes with warfarin therapy appears credible and warrants further investigation...
  18. ncbi High-impact articles related to the pharmacotherapeutic management of systolic heart failure
    Tien M H Ng
    School of Pharmacy, University of Southern California, Los Angeles, California, 90033, USA
    Pharmacotherapy 24:1594-633. 2004
    ..This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students...
  19. ncbi Vasopressin: a new target for the treatment of heart failure
    Craig R Lee
    School of Pharmacy, University of North Carolina at Chapel Hill, 27599-7075, USA
    Am Heart J 146:9-18. 2003
    ....
  20. ncbi beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure
    Steven G Terra
    Department of Pharmacy Practice, University of Florida, Gainsville, FL 32610, USA
    Clin Pharmacol Ther 77:127-37. 2005
    ..We also tested whether polymorphisms in the beta(2)-adrenergic receptor, G-protein alpha s subunit (G(s)alpha), and cytochrome P450 (CYP) 2D6 genes or S-metoprolol plasma concentrations were associated with beta-blocker tolerability...
  21. ncbi Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
    Steven G Terra
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 15:227-34. 2005
    ..We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the beta1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to beta-blocker therapy among heart failure patients...
  22. ncbi Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction
    Francois Alla
    Department of Epidemiology, University Hospital of Nancy, Nancy, France
    Am Heart J 153:1074-80. 2007
    ..Whether women with chronic heart failure are at less risk for hospitalization for worsening heart failure has not been well investigated...
  23. ncbi Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study
    Craig R Lee
    Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health Research, Triangle Park, NC 27709, USA
    Hum Mol Genet 15:1640-9. 2006
    ..315). Genetic variation in EPHX2 was significantly associated with risk of incident CHD in Caucasians, implicating EPHX2 as a potential cardiovascular disease-susceptibility gene...
  24. ncbi Warfarin initiation and the potential role of genomic-guided dosing
    Craig R Lee
    Clin Med Res 3:205-6. 2005
  25. ncbi Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity
    Craig R Lee
    Eur J Clin Pharmacol 61:315-6. 2005
  26. ncbi Surrogate end points in heart failure
    Craig R Lee
    School of Pharmacy, Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599-7360, USA
    Ann Pharmacother 36:479-88. 2002
    ..Further investigation of these measures is required before routine implementation in drug development and clinical practice can be justified...

Research Grants3

  1. CYP2J2 Derived Eicosanoids and Endothelial Function
    Craig Lee; Fiscal Year: 2005
    ..abstract_text> ..
  2. Cytochrome P450 Derived Eicosanoids and Inflammation
    Craig R Lee; Fiscal Year: 2010
    ....